Overall, it has been demonstrated that reduction of GPC1 activity through molecular or pharmacological interventions results in suppression of growth factor induced tumor cell growth, suggesting the potential of GPC1 as a druggable therapeutic target [16, 28, 29]. This evidence concerns the gene GPC1 and neoplasm.